Literature DB >> 18237801

Factors associated with radiation-induced nausea and vomiting in head and neck cancer patients treated with intensity modulated radiation therapy.

Alan T Monroe1, Sathya C Reddy, Gregory L Gibbs, Gerald A White, Anuj V Peddada.   

Abstract

BACKGROUND AND
PURPOSE: To investigate factors associated with radiation-induced nausea and vomiting (RINV) in the setting of head and neck intensity modulated radiation therapy (IMRT).
MATERIALS AND METHODS: Forty-three patients treated with IMRT for head and neck cancer between 2002 and 2007 comprise the cohort. The majority (79%) were treated with an accelerated altered fractionation scheme, and concurrent chemotherapy was delivered to 23. A retrospective review of factors associated with nausea was performed.
RESULTS: Eighteen patients (42%) reported grade 1 acute nausea, and seven patients (16%) reported grade 2 nausea. Factors significant for grade 1-2 nausea on univariate analysis included dose to the dorsal vagal complex of the mid-medulla, younger age, use of a low neck field, and Amifostine use. Only young age retained significance on multivariate analysis. High-grade nausea was associated with use of Amifostine (p=0.003) and concurrent chemotherapy (p=0.015).
CONCLUSIONS: In addition to previously recognized emetic factors, young age and radiation dose to the dorsal vagal complex of the brainstem may play a role in development of nausea during head and neck IMRT.

Entities:  

Mesh:

Year:  2008        PMID: 18237801     DOI: 10.1016/j.radonc.2007.12.030

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  7 in total

1.  The biobehavioral and neuroimmune impact of low-dose ionizing radiation.

Authors:  Jason M York; Neil A Blevins; Daryl D Meling; Molly B Peterlin; Daila S Gridley; Keith A Cengel; Gregory G Freund
Journal:  Brain Behav Immun       Date:  2011-09-21       Impact factor: 7.217

2.  Patient- and treatment-related risk factors for nausea and emesis during concurrent chemoradiotherapy.

Authors:  Ingeborg Fraunholz; Katharina Grau; Christian Weiss; Claus Rödel
Journal:  Strahlenther Onkol       Date:  2010-12-22       Impact factor: 3.621

3.  Moderate to severe nausea in radioactive iodine (RAI) therapy is associated with the RAI dose per body weight and was not prevented by ramosetron.

Authors:  Toshiyuki Ikeoka; Takao Ando; Misa Imaizumi; Ikuko Ueki; Toshiro Usa; Atsushi Kawakami
Journal:  Endocrine       Date:  2014-05       Impact factor: 3.633

4.  Post-Irradiated Human Submandibular Glands Display High Collagen Deposition, Disorganized Cell Junctions, and an Increased Number of Adipocytes.

Authors:  Kihoon Nam; Christina L Maruyama; Bryan G Trump; Luke Buchmann; Jason P Hunt; Marcus M Monroe; Olga J Baker
Journal:  J Histochem Cytochem       Date:  2016-04-28       Impact factor: 2.479

5.  Beam path toxicity in candidate organs-at-risk: assessment of radiation emetogenesis for patients receiving head and neck intensity modulated radiotherapy.

Authors:  Esengul Kocak-Uzel; G Brandon Gunn; Rivka R Colen; Micheal E Kantor; Abdallah S R Mohamed; Sara Schoultz-Henley; Paniyotis Mavroidis; Steven J Frank; Adam S Garden; Beth M Beadle; William H Morrison; Jack Phan; David I Rosenthal; Clifton D Fuller
Journal:  Radiother Oncol       Date:  2014-04-17       Impact factor: 6.280

6.  Correlation of Planned Dose to Area Postrema and Dorsal Vagal Complex with Clinical Symptoms of Nausea and Vomiting in Oropharyngeal Cancer (OPC) patients treated with radiation alone using IMRT.

Authors:  Tony J C Wang; Sandra Fontenla; Patrick McCann; Robert J Young; Stephen McNamara; Shyam Rao; James G Mechalakos; Nancy Y Lee
Journal:  J Radiat Oncol       Date:  2013-02-28

7.  Correlation between delivered radiation doses to the brainstem or vestibular organ and nausea & vomiting toxicity in patients with head and neck cancers - an observational clinical trial.

Authors:  Kilian Schiller; Hanno Martin Specht; Bernhard Haller; Daniela Hallqvist; Michal Devecka; Aaron Becker von Rose; Stephanie Elisabeth Combs; Steffi Pigorsch
Journal:  Radiat Oncol       Date:  2017-07-04       Impact factor: 3.481

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.